Condition
EGFR Exon 20 Insertion Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 4 EGFR Exon 20 Insertion Mutation clinical trials that are recruiting, at sites in 2 countries (most in France (2), China (2)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest EGFR Exon 20 Insertion Mutation clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer | — | Aix-en-Provence and 15 other locations | Recruiting | May 1, 2026 |
| BEBT-109 treatment for lung cancer with specific mutations | Phase 2 | Guangzhou, Guangdong and 1 other locations | Recruiting | Nov 26, 2024 |
| Understanding resistance to amivantamab in lung cancer patients | — | Bordeaux and 17 other locations | Recruiting | Feb 8, 2024 |
| Assessing furmonertinib for lung cancer patients with specific mutations after surgery | Phase 2 | Chengdu, Sichuan | Recruiting | Jan 5, 2024 |
All recruiting trials (4)
-
Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer
This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.
-
BEBT-109 treatment for lung cancer with specific mutations
This study is testing a new drug called BEBT-109 to see if it can help people with a specific type of lung cancer that has certain mutations, especially those who haven't had much success with other treatments.
-
Understanding resistance to amivantamab in lung cancer patients
This study is trying to understand why some lung cancer patients with a specific mutation stop responding to the drug amivantamab, by looking at their blood and tumor samples after their disease gets worse.
-
Assessing furmonertinib for lung cancer patients with specific mutations after surgery
This study is testing if a new drug called furmonertinib can help lung cancer patients with specific mutations stay cancer-free after their surgery.
Related topics
Quick answers
How many EGFR Exon 20 Insertion Mutation clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in France (2 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.